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Abstract: Brain-derived neurotrophic factor (BDNF) and its tropomyosin-related kinase B (TrkB)
receptor might contribute to normal lung functioning and immune responses; however, their role
in asthma remains unclear. Plasma BDNF concentrations, as well as BDNF and NTRK2 (TrkB gene)
polymorphisms, were investigated in 120 asthma patients and 120 healthy individuals using
enzyme-linked immunosorbent assay and polymerase chain reaction, respectively. The genotype
and allele frequencies of BDNF Val66Met (rs6265) and NTRK2 rs1439050 polymorphisms did not
differ between healthy individuals and asthma patients, nor between patients grouped according
to severity or different asthma phenotypes. Although plasma BDNF concentrations were higher
among healthy subjects carrying the BDNF Val66Met GG genotype compared to the A allele carriers,
such differences were not detected in asthma patients, suggesting the influences of other factors.
Plasma BDNF concentration was not affected by NTRK2 rs1439050 polymorphism. Asthma patients
had higher plasma BDNF concentrations than control subjects; however, no differences were found
between patients subdivided according to asthma severity, or Type-2, allergic, and eosinophilic
asthma. Higher plasma BDNF levels were observed in asthma patients with aspirin sensitivity and
aspirin-exacerbated respiratory disease. These results suggest that plasma BDNF may serve as a
potential peripheral biomarker for asthma, particularly asthma with aspirin sensitivity.
Keywords: asthma; plasma BDNF concentration; BDNF and NTRK2 (TrkB gene) polymorphisms;
severity; phenotypes; aspirin
1. Introduction
Asthma is a chronic inflammatory disease of the airways characterized by the hallmark features
of airway hyperresponsiveness, enhanced bronchial smooth muscle cell contractility, and mucus
overproduction [1]. It is very common, affecting approximately 235 million children and adults
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worldwide [2], and causes tremendous morbidity, mortality, and global socioeconomic burden in both
Europe [3] and the United States [4]. The remarkable heterogeneity of asthma is underpinned by its wide
range of clinical presentations, disease severity, and responses to therapy, as well as the involvement of
different pathophysiological mechanisms and biological pathways [5]. The pathogenesis of asthma
is clearly multifactorial, governed by the complicated interactions between genetic, environmental,
developmental, and immunological risk factors [6]. The overall etiology of this disease, however, is not
yet fully understood and remains to be elucidated.
There is growing evidence in the literature suggesting that the link between inflammation and
neuronal dysfunction in asthma is mainly provided by neurotrophins (a family of growth factors),
notably brain-derived neurotrophic factor (BDNF) [7]. BDNF actions are mediated via binding to its
high affinity receptor located within the cell membrane, tropomyosin-related kinase B (TrkB) [8–10],
causing the activation of the downstream MAPK, PI3K, and PLCγ signaling pathways [11–13].
It has been shown that the majority of vagal (sensory) neurons innervating the lungs are
BDNF-dependent and can affect the functions of motor neurons [14–16]. Both BDNF and its receptor
TrkB are expressed by diverse cell types in the lungs, such as airway smooth muscle cells, fibroblasts,
airway epithelium, neurons, and immune cells [17,18]. BDNF expression and TrkB signaling, as well as
their significance in the normal physiological and pathophysiological processes in the lungs continue
to be explored [17]. Specifically, various stimuli affecting intra- and extracellular BDNF concentration
have been analyzed with a view to understand the relevance of major variations of BDNF levels in
human blood and tissue [19]. A number of studies thus far have sought to investigate the role of BDNF
in the airways by assessing its concentration locally and in the peripheral circulation, as well as by
determining the association between selected polymorphisms in the BDNF and NTRK2 (TrkB) genes
and the development of asthma [9,20].
Discrepancies between these studies in asthma patients, however, highlight the need for further
research in this area [21–24]. The functional BDNF Val66Met (rs6265) variant seems to be particularly
important given that the Met allele has been associated with abnormal cellular trafficking and packaging
of pro-BDNF, resulting in a decreased production of mature BDNF protein in neurons [25,26]. On the
other hand, the NTRK2 rs1439050 is an intronic polymorphism, and therefore, does not have a specific
reported role [27]. Nevertheless, it may still be associated with asthma, albeit not as a vulnerability
factor per se (i.e., directly explaining the phenotype), but rather in linkage disequilibrium with a nearby
unidentified functional mutation in the TrkB gene [27].
Few reports in the literature up to this point have evaluated the possible influence of BDNF and
NTRK2 polymorphic variants on serum and plasma BDNF levels in patients with asthma. However,
recent studies conducted mainly on the pediatric population across several different countries and
ethnicities have produced opposing results [7,15,20,28–32]. These may be due to inconsistencies in the
methodological approaches and types of samples used, for instance, blood (plasma, serum, or platelets),
sputum, or bronchoalveolar lavage fluid.
To date, BDNF as a potential blood biomarker in asthma has not yet been studied in a Croatian
population. Therefore, the aim of our research was to determine the BDNF concentration in the plasma
of asthma patients and control subjects, as well as to investigate the potential association of BDNF
Val66Met and NTRK2 rs1439050 polymorphisms with asthma, its severity and various phenotypes
in an ethnically homogenous group of Caucasian Croatian adults. We hypothesized that plasma
BDNF concentration would be significantly altered in asthma patients compared to healthy subjects,
while BDNF Val66Met and NTRK2 rs1439050 polymorphisms would be associated with asthma,
disease severity, and certain asthma phenotypes.
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2. Materials and Methods
2.1. Participants
This prospective case-control study included a total of 240 subjects of both genders; (120 adult
patients with asthma and a control group of 120 healthy adults). All participants enrolled in the study
were unrelated Croatian Caucasians. Patients who were previously diagnosed by a pulmonologist as
having asthma, and classified according to asthma severity based on the Global Initiative for Asthma
(GINA) classification guidelines [33], were recruited consecutively at their regularly scheduled follow-up
visits at the Outpatient Department of the Clinic for Lung Diseases Jordanovac, University Hospital
Centre Zagreb, in Zagreb, Croatia, from February 2014 to April 2015 and July 2017 to February 2018.
The control group consisted of volunteer blood donors, initially screened for good general health and
an unremarkable medical history to meet the eligibility criteria for blood donation. Healthy controls
were recruited consecutively by the healthcare staff at the Croatian Institute for Transfusion Medicine
in Zagreb, Croatia, during their routine blood donation sessions.
Asthma patients satisfied the following inclusion criteria for enrolment into the study:
adults (18 years of age and older); no airway disease besides asthma; no acute exacerbation at
time of visit; no history of asthma exacerbation or respiratory infection in the previous four weeks;
no immune, infectious, or malignant disease; no serious cardiovascular or gastrointestinal disease,
or poorly controlled comorbidity (e.g., hypertension, chronic kidney disease, diabetes mellitus, etc.).
Healthy control subjects had no history of asthma or other airway diseases, respiratory symptoms,
allergic diseases, or recent infections or inflammation. Asthma patients and healthy adults with a
documented diagnosis of neurodegenerative or neuropsychiatric disorders, substance abuse, and/or use
of anxiolytics, antidepressants, aspirin, or clopidogrel were excluded from the study.
Data pertaining to age, gender, body mass index (BMI), and smoking were collected for both the
healthy controls and asthma patients. BMI, an indicator of relative obesity, was calculated using the
formula BMI = weight (kg)/height2 (m2). Subjects with a BMI of 30 and above were considered obese
according to the World Health Organization criteria. In addition, a complete medical history, physical
examination, and diagnostic work-up were conducted on each asthma patient. Skin prick testing (SPT)
was carried out with common airborne allergens (Stallergen allergenic extracts for skin prick testing with
control solution, Paris, France), with positive (histamine) and negative (saline) controls. Spirometry with
bronchodilation and single-breath diffusing capacity of lung for carbon monoxide (DLCO) tests were
performed using the Master-Screen pulmonary function testing analyzer (Version 5.0, Jaeger GmbH,
Hoechberg, Germany) according to the manufacturer’s guidelines. Forced expiratory volume in one
second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF) were calculated from the
flow-volume loop as the outcome measures using internally derived references. Predicted values for
spirometry and pulmonary diffusing capacity are reference values of the European Community for
Coal and Steel [34,35]. The fractional exhaled nitric oxide (FeNO) measurement was determined using
Denox 88 Module (Eco Medics AG, Duernten, Switzerland). Blood samples were collected in EDTA
tubes, and the eosinophil and neutrophil counts were obtained from automated complete blood counts.
Total serum immunoglobulin E (IgE) levels were measured using enzyme amplified chemiluminescent
immunoassays (Immulite® 2000XPi, Siemens Healthcare Diagnostics, Erlangen, Germany), on Siemens
Immulite® 2000XPi automated analyzer, according to the manufacturer’s instructions.
The asthma patients were subdivided into non-severe (mild to moderate) and severe asthma in
keeping with the GINA guidelines [33]. Moreover, they were categorized into non-allergic and allergic
asthma based on the patient’s clinical history, physical examination, and SPT or extract-based IgE
testing [36]. Asthma patients with (≥300 cells/µL) or without (<300 cells/µL) high blood eosinophil
count were classified as having eosinophilic or non-eosinophilic asthma, respectively [37]. Subjects with
asthma were also divided into Type 2 (T2)-high and T2-low groups according to their phenotypic
characteristics [38–40]. Patients were identified as T2-high if they were allergic (i.e., positive SPT
and/or increased level of total IgE (>120 kU/L) or positive specific IgE), had eosinophilic asthma
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(i.e., high blood eosinophil count ≥ 300 cells/µL), increased value of FeNO > 25 ppb, or exercise-induced
asthma (EIA). Patients were considered T2-low if they did not possess any of the aforementioned
disease features, but were smokers or obese with BMI > 30 [41]. Patients with the combination of
asthma, recurrent nasal polyps, and sensitivity to aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs) were classified as having aspirin-exacerbated respiratory disease (AERD), also known
as Samter’s Triad [42], and compared to asthma patients without AERD.
Written informed consent was obtained from each subject prior to participating in the research.
The study protocol was approved by the local Ethics Committees of the University Hospital Centre
Zagreb, Croatian Institute for Transfusion Medicine, and University of Zagreb, School of Medicine
(Project: Person-centered phenotype and genotype research of patients with asthma, Permission No:
02/21 AG). The research was conducted in accordance with the ethical standards laid down by the
Declaration of Helsinki of 1975.
2.2. Data and Blood Collection
Demographic and clinical data were recorded for each study participant. Whole blood samples
were obtained in the mornings (between 7 and 9 a.m.) after an overnight fast to minimize possible
circadian variations. Peripheral venous blood samples (8.5 mL) were drawn into tubes containing
1.5 mL of acid-citrate-dextrose anticoagulant solution, immediately refrigerated at a temperature of
4 ◦C, and then transported to the Rudjer Boskovic Institute in Zagreb, Croatia, for processing within an
hour of arrival.
2.3. Determination of Plasma BDNF Concentration
Plasma samples for BDNF analysis were obtained by a series of centrifugations of the whole
blood. Plasma BDNF concentrations were determined in duplicate by enzyme-linked immunosorbent
assay (ELISA) using a commercial kit (Quantikine® ELISA Human Free BDNF Immunoassay,
R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s guidelines. After terminating
the antibody-enzyme-substrate reaction, the optical density in each well was determined using an
ELISA microplate reader set to 450 nm, with wavelength correction set to 570 nm. The BDNF plasma
concentrations of the samples in each assayed plate were calculated based on the standard curve.
The intra- and inter-assay coefficients of variations were minimal (less than 10%).
2.4. DNA Extraction and Genotyping
Genomic DNA was isolated from peripheral blood leukocytes using a salting-out method [43].
The BDNF Val66Met (rs6265) and NTRK2 rs1439050 gene polymorphisms were genotyped with TaqMan
SNP Genotyping Assay (Applied Biosystems®, Foster City, CA, USA) using real-time polymerase chain
reaction (PCR) conducted on an ABI Prism® 7000 Sequence Detection System apparatus according
to the manufacturer’s instructions. Briefly, 20 ng of genomic DNA was amplified in a 10-µL reaction
volume under the following PCR reaction conditions: 40 cycles at 92 ◦C for 15 s and 60 ◦C for 60 s.
2.5. Statistical Analysis
Statistical analyses were performed using GraphPad Prism version 4.00 for Windows (GraphPad
Software, Inc., San Diego, CA, USA). The data were expressed as number (n) and percentage (%) for
categorical data or as median with 25th (Q1) and 75th (Q3) percentiles for numerical (continuous) data.
All examined parameters failed the assumption of normality of distribution according to the D’Agostino
& Pearson omnibus test. Therefore, non-parametric analyses were used to compare the independent
cohorts. Continuous variables were compared using Mann-Whitney U test (for comparison of two
groups) or Kruskal-Wallis test with post-hoc Dunn’s multiple comparisons test (for comparison
of three or more groups). Correlations were assessed with non-parametric Spearman correlation.
Possible deviations from the Hardy-Weinberg equilibrium (HWE) were tested using the goodness of fit
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χ2-test. Genotype and allele frequencies were evaluated by a χ2-test of independence or Fisher exact
test, respectively.
The obtained results were corrected for multiple testing (five comparisons of asthma phenotypes:
non-severe vs. severe; T2-high vs. T2-low; non-allergic vs. allergic; non-eosinophilic vs. eosinophilic;
non-AERD vs. AERD) using Bonferroni correction, and statistical significance was defined as p-value
less than 0.01. A priori sample size and achieved power calculations were conducted using the G*Power
3 Software Version 3.1.9.2. (Free program written by Franz Faul, University of Kiel, Kiel, Germany).
For Mann-Whitney test, at medium effect size 0.425, power 0.8, and statistical significance set at 0.01,
an adequate total sample size was determined to be 236. For Kruskal-Wallis test (three groups) at
medium effect size 0.25, power 0.8, and statistical significance set at 0.01, an adequate sample size was
determined to be 228. For χ2-test (df = 2), at small-to-medium effect size 0.25, power 0.8, and statistical
significance set at 0.01, an adequate sample size was determined to be 223, whereas for Fisher exact
test (df = 1) at small-to-medium effect size 0.25, power 0.8, and statistical significance set at 0.01,
an adequate sample size was determined to be 187. Given that the actual total sample size was 240,
the power analysis confirmed the appropriate sample size and statistical power of the study.
3. Results
A total of 120 asthma cases (41 males and 79 females) and 120 control subjects (73 males and
47 females) were examined (Table 1). There were more males (60.83%) in the control group (p < 0.0001),
while females predominated (p < 0.0001) in the asthma group. Asthma patients were significantly
older (p < 0.0001) than healthy individuals, and this age disparity was due to the significantly older
individuals (61.00 years, 53.00–67.50) in the group of severe asthma patients.
Table 1. Characteristics of asthma patients and healthy subjects.
Parameter Asthma Patients(n = 120)
Healthy Controls
(n = 120) Statistical Analysis
Age (years)
Median (25%; 75%)
58.00
(40.25; 67.00)
42.00
(33.25; 51.00)
p < 0.0001; U = 3912.00
Mann-Whitney test
Males
n (%)
41
(34.17)
73
(60.83)
p < 0.0001
Fisher’s exact test
Current smokers
n (%)
10
(8.33)
41
(34.17)
p = 0.0005
Fisher’s exact test
BMI (kg/m2)
Median (25%; 75%)
26.65
(23.03; 29.80)
26.20
(23.33; 28.85)
p = 0.64; U = 6949.00
Mann-Whitney test
BMI category: Normal weight
(18.5–24.9 kg/m2), n (%)
44
(36.67)
43
(35.83)
p = 0.48; χ2 = 4.52
χ2-test
BMI category: Obesity
(≥30 kg/m2), n (%)
28
(23.33)
22
(18.33)
p = 0.43
Fisher’s exact test
BMI = Body mass index.
Specifically, further analysis by Kruskal-Wallis test, followed by Dunn’s multiple comparisons
test, demonstrated that the group of severe asthma patients (n = 61) was significantly older than the
group (n = 59) of non-severe asthma patients (47.00 years, 35.00–67.00; p = 0.005), and the control
group (42.00 years, 33.25–51.00; p < 0.0001). Significantly fewer patients with asthma (8.33%) than
healthy subjects (34.17%) were current smokers (p = 0.0005), although non-smokers (never and past
smokers) were more prevalent (p < 0.0001) in both groups (Table 1). On the other hand, there were
no differences in BMI (p = 0.64) between asthma cases and healthy controls, even across six different
BMI categories (p = 0.48), including underweight, normal weight, overweight, and three categories of
obesity, or when the subjects were divided into obese or non-obese individuals (p = 0.43). As shown in
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Figure 1, plasma BDNF concentrations were significantly higher (p < 0.0001) in asthma patients in
comparison to the healthy subjects.Bio edicines 2020, 8, x FOR PEER REVIEW 6 of 20 
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0.03) than healthy carriers of the GG genotype (Table 3). Moreover, plasma BDNF concentrations in 
Figure 1. Plasma brain-derived neurotrophic factor (BDNF) concentrations were significantly higher in
the asthma patients (0.89 pg/mL, 0.59–1.22) as compared to the healthy subjects (0.59 pg/mL, 0.45–0.92).
* p < 0.0001, U = 4902.00, Mann-Whitney test.
There was no significant correlation between plasma BDNF levels and age in asthma patients
(p = 0.49, r = 0.06) and control group (p = 0.84, r = −0.02). The concentration of BDNF in plasma was
not significantly correlated with the BMI of asthma patients (p = 0.17, r = 0.13) or healthy subjects
(p = 0.54, r = 0.06). There were also no significant differences in plasma BDNF levels between smokers
and non-smokers in the control (p = 0.23) and asthma (p = 0.07) groups. When the asthma patients and
control subjects were subdivided according to gender, we observed no significant differences in plasma
BDNF levels between male and female asthma patients (p = 0.67), whereas healthy males had nominally
higher BDNF concentrations in plasma than healthy females (p = 0.04); however, this difference was
not significant after applying the correction for multiple testing.
The BDNF Val66Met genotype distributions were in HWE for both the control group (p = 0.38)
and asthma patients (p = 0.26). As demonstrated in Table 2, the BDNF Val66Met genotype (p = 0.54)
and allele (p = 0.35) frequencies did not differ significantly between healthy subjects and asthma
patients. A comparison of the carriers of GG homogenous genotype and A allele carriers revealed no
significant difference in their distribution (p = 0.34) between healthy individuals and asthma patients.
Likewise, the G versus AA carrier frequencies did not differ significantly (p = 1.00) between these
groups (Table 2).
Table 2. Distribution of genotypes, alleles and carriers of BDNF Val66Met polymorphism in asthma
patients and healthy subjects.
BDNF Val66Met
Polymorphism
Asthma Patients
n (%)
Healthy Controls
n (%) Statistical Analysis
Genotypes
AA 3 (2.50) 2 (1.67) p = 0.54;
χ2 = 1.23
χ2-test
AG 43 (35.83) 36 (30.00)
GG 74 (61.67) 82 (68.33)
Alleles
A 49 (20.42) 40 (16.67) p = 0.35
Fisher’s exact testG 191 (79.58) 200 (83.33)
Carriers
A 46 (38.33) ( . ) p = 0.34
Fisher’s exact testGG 74 (61.67) 82 (68.33)
G 117 (97.50) ( . ) p = 1.00
Fisher’s exact testAA 3 (2.50) ( . )
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A difference in the plasma BDNF concentrations of the control subjects was observed when the
asthma patients and healthy individuals were subdivided according to BDNF Val66Met genotype;
healthy carriers of the AG genotype were found to have nominally lower BDNF concentrations
(p = 0.03) than healthy carriers of the GG genotype (Table 3). Moreover, plasma BDNF concentrations
in the control group were significantly decreased (p = 0.008) among carriers of the A allele when
compared to GG carriers. Healthy carriers of the G allele, however, did not have significantly different
plasma BDNF concentrations (p = 0.65) than the AA genotype carriers.
Table 3. Plasma BDNF concentration in asthma patients and healthy subjects carrying different BDNF
Val66Met genotypes and alleles.
BDNF Val66Met
Polymorphism
Asthma Patients Healthy Subjects
Plasma BDNF
Concentration (pg/mL)
Median (25%; 75%)
Statistical Analysis
Plasma BDNF
Concentration (pg/mL),
Median (25%; 75%)
Statistical Analysis
Genotypes
AA 0.45 (0.43; 1.24)
p = 0.52
Kruskal-Wallis test
0.56 (0.47; 0.65)
p = 0.03
Kruskal-Wallis test *
AG 0.81 (0.52; 1.35) 0.51 (0.32; 0.73)
GG 0.94 (0.62; 0.94) 0.68 (0.49; 1.05)
Carriers
A 0.80 (0.46; 1.34) p = 0.39; U = 1544.00
Mann-Whitney test
0.51 (0.35; 0.70) p = 0.008; U = 1089.00
Mann-Whitney testGG 0.94 (0.62; 1.20) 0.68 (0.49; 1.05)
G 0.91 (0.61; 1.22) p = 0.37; U = 120.50
Mann-Whitney test
0.59 (0.45; 0.93) p = 0.64; U = 94.50
Mann-Whitney testAA 0.45 (0.43; 1.24) 0.56 (0.47; 0.65)
BDNF = Brain-derived neurotrophic factor; * AG vs. GG, p = 0.03 Dunn’s multiple comparisons test.
On the other hand, there were no significant differences in plasma BDNF concentrations (p = 0.52)
of asthma patients split into groups based on BDNF Val66Met genotype (Table 3). There were no
significant differences in the plasma BDNF concentrations between asthma patients carrying the A
allele and GG genotype (p = 0.39), as well as between asthmatic carriers of G allele and AA homozygous
genotype (p = 0.37).
The NTRK2 rs1439050 genotype distributions were also in HWE for both the control group
(p = 0.34) and the individuals with asthma (p = 0.40). The NTRK2 rs1439050 genotype (p = 0.86) and
allele (p = 0.68) frequencies did not differ significantly between healthy participants and asthma patients
(Table 4). As demonstrated in Table 4, the G versus TT carrier frequencies did not differ significantly
(p = 1.00) between these groups. In addition, no significant difference (p = 0.70) in the distribution of
GG homogenous genotype and T allele carriers was observed between healthy individuals and those
with asthma.
Table 4. Distribution of genotypes, alleles and carriers of NTRK2 rs1439050 polymorphism in asthma
patients and healthy subjects.
NTRK2 rs1439050
Polymorphism
Asthma Patients
n (%)
Healthy Controls
n (%) Statistical Analysis
Genotypes
GG 65 (54.17) 61 (50.83) p = 0.86;
χ2 = 0.29
χ2-test
GT 49 (40.83) 52 (43.33)
TT 6 (5.00) 7 (5.83)
Alleles
G 179 (74.58) 174 (72.50) p = 0.68
Fisher’s exact testT 61 (25.42) 66 (27.50)
Carriers
G 114 (95.00) 113 (94.17) p = 1.00
Fisher’s exact testTT 6 (5.00) 7 (5.83)
T 55 (45.83) 59 (49.17) p = 0.70
Fisher’s exact testGG 65 (54.17) 61 (50.83)
We also investigated whether rs1439050 polymorphic variants, located within the NTRK2
gene encoding the TrkB receptor, influence the plasma level of unbound/active BDNF protein.
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As demonstrated in Table 5, there were no significant differences in plasma BDNF concentrations of
healthy subjects (p = 0.42) or asthma patients (p = 0.13) split into groups based on NTRK2 rs1439050
genotype. There were also no significant differences in the plasma BDNF levels between healthy
individuals (p = 0.52) or asthma patients (p = 0.23) carrying the G allele and TT genotype, as well
as between healthy (p = 0.36) or asthmatic carriers (p = 0.21) of T allele and GG homozygous
genotype (Table 5).
Table 5. Plasma BDNF concentration in asthma patients and healthy subjects carrying different NTRK2
rs1439050 genotypes and alleles.
NTRK2
rs1439050
Polymorphism
Asthma Patients Healthy Subjects
Plasma BDNF
Concentration (pg/mL)
Median (25%; 75%)
Statistical Analysis
Plasma BDNF
Concentration (pg/mL),
Median (25%; 75%)
Statistical Analysis
Genotypes
GG 0.81 (0.59; 1.15)
p = 0.13
Kruskal-Wallis test
0.59 (0.49; 0.94)
p = 0.42
Kruskal-Wallis test
GT 0.97 (0.63; 1.37) 0.59 (0.39; 0.84)
TT 0.51 (0.41; 1.37) 0.65 (0.30; 1.48)
Carriers
G 0.91 (0.61; 1.22) p = 0.23; U = 241.5
Mann-Whitney test
0.59 (0.45; 0.90) p = 0.52; U = 336.5
Mann-Whitney testTT 0.51 (0.41; 1.37) 0.65 (0.30; 1.48)
T 0.97 (0.58; 1.37) p = 0.21; U = 1550
Mann-Whitney test
0.60 (0.39; 0.88) p = 0.36; U = 1623
Mann-Whitney testGG 0.81 (0.59; 1.15) 0.59 (0.49; 0.94)
We also examined the relationship between plasma BDNF levels and asthma severity. As shown
in Figure 2, plasma BDNF concentrations did not differ significantly between the non-severe and severe
asthma patients (p = 0.71).
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Figure 2. Plasma BDNF concentrations did not differ significantly between the non-severe (0.91 pg/mL,
0.50–1.22) and severe (0.88 pg/mL, 0.61–1.29) asthma patients. p = 0.7094, U = 1728.00, Mann Whitney test.
This finding was confirmed by additional analysis with Kruskal-Wallis test, followed by Dunn’s
multiple comparisons test. Plasma BDNF levels were significantly higher in both non-severe (0.91 pg/mL,
0.50–1.22; p = 0.005) and severe asthma patients (0.88 pg/mL, 0.61–1.29; p = 0.0004) compared to the
control group (0.56 pg/mL, 0.45–0.92). There were no significant differences in the BDNF Val66Met
genotype (p = 0.13) and allele (p = 0.11) frequencies between non-severe and severe asthmatics (Table 6).
As shown in Table 6, no significant differences between non-severe and severe asthma patients were
observed in the distribution of the carriers of the GG genotype and the A allele (p = 0.19), as well as in
the frequencies of G allele and AA genotype carriers (p = 0.24).
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Table 6. Distribution of genotypes, alleles and carriers of BDNF Val66Met polymorphism in non-severe
and severe asthma patients.
BDNF Val66Met
Polymorphism
Non-Severe Asthma Patients,
n (%)
Severe Asthma Patients,
n (%) Statistical Analysis
Genotypes
AA 0 (0.00) 3 (4.92) p = 0.13;
χ2 = 4.04
χ2-test
AG 19 (32.20) 24 (39.34)
GG 40 (67.80) 34 (55.74)
Alleles
A 19 (16.10) 30 (24.59) p = 0.11
Fisher’s exact testG 99 (73.90) 92 (75.41)
Carriers
A 19 (32.20) 27 (44.26) p = 0.19
Fisher’s exact testGG 40 (67.80) 34 (55.74)
G 59 (100.00) 58 (95.08) p = 0.24
Fisher’s exact testAA 0 (0.00) 3 (4.92)
Moreover, there were no significant differences in the NTRK2 rs1439050 genotype (p = 0.56)
and allele (p = 1.00) frequencies between the non-severe and severe asthma patients (Table 7).
As demonstrated in Table 7, no significant differences between the non-severe and severe asthma
patients were detected in the distribution of the carriers of the TT genotype and the G allele (p = 0.43),
as well as in the frequencies of T allele and GG genotype carriers (p = 0.72).
Table 7. Distribution of genotypes, alleles and carriers of NTRK2 rs1439050 polymorphism in non-severe
and severe asthma patients.
NTRK2 rs1439050
Polymorphism
Non-Severe Asthma Patients,
n (%)
Severe Asthma Patients,
n (%) Statistical Analysis
Genotypes
GG 33 (55.93) 32 (52.46) p = 0.56;
χ2 = 1.16
χ2-test
GT 22 (37.29) 27 (44.26)
TT 4 (6.78) 2 (3.28)
Alleles
G 88 (74.58) 91 (74.59) p = 1.00
Fisher’s exact testT 30 (25.42) 31 (25.41)
Carriers
G 55 (93.22) 59 (96.72) p = 0.43
Fisher’s exact testTT 4 (6.78) 2 (3.28)
T 26 (44.07) 29 (47.54) p = 0.72
Fisher’s exact testGG 33 (55.93) 32 (52.46)
Asthma patients demonstrated high heterogeneity in their clinical symptoms and phenotypes
as evidenced by the data in their medical records (summarized in Table 8). A positive correlation
(p = 0.023, r = 0.21) was observed between plasma BDNF concentration and duration of disease in
asthma patients (Table 8), although this result was not significant after correcting for multiple testing.
On the other hand, asthma patients with a history of pneumonia (0.69 pg/mL, 0.48–0.92) had nominally
lower plasma BDNF concentrations (p = 0.026) in comparison to asthma patients who had previously
never developed pneumonia (0.95 pg/mL, 0.61–1.29). Plasma BDNF concentrations were nominally
higher (p = 0.025) in asthma patients with nasal polyps (1.12 pg/mL, 0.72–1.35) versus those without
(0.81 pg/mL, 0.58–1.15). Furthermore, asthma patients with sensitivity to aspirin (1.22 pg/mL, 0.93–1.77)
had significantly higher BDNF levels in plasma (p = 0.009) than asthma patients lacking aspirin
sensitivity (0.84 pg/mL, 0.57–1.18) (Table 8).
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Table 8. The association of plasma BDNF concentration with clinical characteristics in asthma patients.
Clinical Characteristics Median (25%; 75%) Plasma BDNF Concentration (pg/mL)
Total Serum IgE (IU/mL) 191.00 (43.00; 398.00) p = 0.50; Spearman correlation r = −0.06
Blood eosinophils (×109/L) 0.215 (0.10; 0.40) p = 0.69; Spearman correlation r = 0.04
Blood neutrophils (×109/L) 4.560 (3.62; 6.30) p = 0.92; Spearman correlation r = −0.01
FeNO (ppb) 34.00 (14.28; 67.75) p = 0.98; Spearman correlation r = −0.002
FEV1 (% of predicted value) 74.90 (54.28; 90.08) p = 0.41; Spearman correlation r = 0.07
FVC (% of predicted value) 88.50 (75.08; 101.80) p = 0.65; Spearman correlation r = −0.04
PEF (% of predicted value) 77.05 (57.25; 95.52) p = 0.58; Spearman correlation r = −0.05
DLCO (%) 83.30 (73.68; 95.35) p = 0.055: Spearman correlation r = −0.17
Duration of disease (years) 13.50 (8.00; 29.00) p = 0.023; Spearman correlation r = 0.21
Comorbidities (n) 2.00 (1.25; 4.00) p = 0.35; Spearman correlation r = 0.08
Clinical Characteristics n (%) Plasma BDNF Concentration (pg/mL)
Penicillin allergy 25 (20.83) p = 0.18; U = 977.50; Mann-Whitney test
Nutritive allergy 12 (10.00) p = 0.10; U = 458.50; Mann-Whitney test
Animal dander/feather allergy 18 (15.00) p = 0.31; U = 779.00; Mann-Whitney test
Dust allergy 51 (42.50) p = 0.06; U = 1408.00; Mann-Whitney test
Pollen allergy 53 (44.17) p = 0.72; U = 1709.00; Mann-Whitney test
Fungal/mold allergy 9 (7.50) p = 0.28; U = 390.50; Mann-Whitney test
Early onset asthma (age < 12 years) 21 (17.50) p = 0.12; U = 817.00; Mann-Whitney test
History of pneumonia 21 (17.50) p = 0.026; U = 718.00; Mann-Whitney test
Emergency intervention (ever) 89 (74.17) p = 0.53; U = 1274.00; Mann-Whitney test
Hospitalization for asthma (ever) 58 (48.33) p = 0.70; U = 1724.00; Mann-Whitney test
Nasal polyps 27 (22.50) p = 0.025; U = 891.00; Mann-Whitney test
Aspirin sensitivity 11 (9.17) p = 0.009; U = 314.00; Mann-Whitney test
Allergen specific immunotherapy 15 (12.50) p = 0.99; U = 787.00; Mann-Whitney test
Oral corticosteroid therapy 30 (25.00) p = 0.58; U = 1258.00; Mann-Whitney test
Biological therapy 20 (16.67) p = 0.80; U = 962.50; Mann-Whitney test
DLCO = diffusing capacity of lung for carbon monoxide; FeNO = fractional exhaled nitric oxide; FEV1 = forced
expiratory volume in one second; FVC = forced vital capacity; IgE = immunoglobulin E; PEF = peak expiratory
flow; ppb = parts per billion.
In addition, we investigated the plasma BDNF concentrations in various asthma phenotypes.
As shown in Table 9, we found no differences in the plasma BDNF concentrations between asthma
patients with T2-high and T2-low (p = 0.43), non-allergic and allergic (p = 0.41), and eosinophilic
versus non-eosinophilic asthma (p = 0.54) phenotypes. However, patients with AERD demonstrated
nominally higher plasma BDNF concentrations (p = 0.017) than those without AERD (Table 9).
Table 9. Plasma BDNF concentration in patients with different asthma phenotypes.
Asthma
Phenotypes
Plasma BDNF Concentration (pg/mL)
Median (25%, 75%)
Statistical
Analysis
T2-high (n = 94) 0.91 (0.60; 1.30) p = 0.43;
U = 1097.00
Mann-Whitney test
T2-low (n = 26) 0.82 (0.42; 1.14)
Non-allergic (n = 42) 0.98 (0.60; 1.29) p = 0.41;
U = 1487.00
Mann-Whitney test
Allergic (n = 78) 0.82 (0.58; 1.20)
Non-eosinophilic (n = 73) 0.92 (0.54; 1.20) p = 0.54;
U = 1602.00
Mann-Whitney test
Eosinophilic (n = 47) 0.88 (0.61; 1.34)
Non-AERD (n = 111) 0.85 (0.58; 1.18) p = 0.017;
U = 262.00
Mann-Whitney test
AERD (n = 9) 1.22 (0.92; 2.05)
AERD = aspirin-exacerbated respiratory disease.
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There were no significant differences in the distribution of the BDNF Val66Met genotypes (p = 0.50),
alleles (p = 0.44), GG vs. A allele carriers (p = 0.49), and AA vs. G carriers (p = 1.00) between asthma
patients with T2-high and T2-low phenotypes. In addition, the frequencies of BDNF Val66Met genotypes
(p = 0.27), alleles (p = 0.18), GG vs. A allele carriers (p = 0.24), and AA vs. G carriers (p = 0.55) were
not significantly different between non-allergic and allergic asthma patients. Moreover, we observed
no significant differences in the frequencies of BDNF Val66Met genotypes (p = 0.60), alleles (p = 0.62),
GG vs. A allele carriers (p = 0.71), as well as AA vs. G carriers (p = 0.56), between patients with and
without eosinophilic asthma. There were also no significant differences in the distribution of the BDNF
Val66Met genotypes (p = 0.86), alleles (p = 1.00), GG vs. A allele carriers (p = 1.00), as well as AA vs. G
carriers (p = 1.00), between asthma patients with and without AERD (data available on request).
The distribution of the NTRK2 rs1439050 genotypes (p = 0.14), alleles (p = 0.07), GG vs. T allele
carriers (p = 0.55), and TT vs. G carriers (p = 0.34) was not significantly different between asthma
patients with T2-high and T2-low phenotypes. Moreover, we observed no significant differences in the
frequencies of NTRK2 rs1439050 genotypes (p = 0.09), alleles (p = 0.06), GG vs. T allele carriers (p = 0.13),
and TT vs. G carriers (p = 0.09) between non-allergic and allergic asthma patients. The frequencies of
NTRK2 rs1439050 genotypes (p = 0.78), alleles (p = 0.76), GG vs. T allele carriers (p = 0.58), as well as TT
vs. G carriers (p = 1.00) were not significantly different between patients with and without eosinophilic
asthma. In addition, asthma patients with and without AERD did not differ in their distribution of the
NTRK2 rs1439050 genotypes (p = 0.77), alleles (p = 1.00), GG vs. T allele carriers (p = 1.00), as well as
TT vs. G carriers (p = 1.00) (data available on request).
4. Discussion
To the best of our knowledge, the present study is the first to investigate the plasma BDNF,
BDNF Val66Met and NTRK2 rs1439050 polymorphisms in adult asthma patients and healthy
control subjects of the same ethnic and racial background (i.e., Croatian Caucasians). Our findings,
demonstrating that control subjects were significantly younger than asthma patients and consisted
mainly of men, are in line with the data about blood donors in Croatia, with a median age of 37–40 years
and a male predominance of 83.9% [44,45]. The results of our study, showing that the asthma group
was older and consisted predominantly of females, are in keeping with the literature reporting that
after puberty, women continue to have a higher burden of asthma than males, and this trend continues
well into the 5th decade of life [46,47]. In addition, it is not surprising that the observed age difference
is due to the significantly older individuals in the group of severe asthma patients, considering the fact
that asthma is more severe in older adults and in patients with longer asthma duration [48]. Our results
showing that healthy subjects actively smoked more than asthma patients are not unexpected since
many asthma patients (30.83% in our study) quit smoking because of more severe asthma symptoms,
in addition to the benefit of smoking cessation in improving lung function [49]. The observed 34.17%
of smokers in the control group is consistent with the smoking frequency (37.45%) in the general
population of Croatia [50]. On the other hand, the 8.33% of active smokers in the asthma group are in
line with the reports of smoking among asthma patients in Brazil and Spain, but much lower than
what is seen in many other countries [51].
Regarding BDNF concentration in plasma, our findings are in agreement with the results of
our previous study showing no significant effects of age, gender, BMI, or smoking on plasma BDNF
values [52]. On the other hand, the study of Pillai et al. (2012) found a negative correlation of plasma
BDNF levels with age, as well as lower plasma BDNF levels in females than males, possibly because
of the weight differences; however, there was no correlation between BDNF plasma concentration
and BMI [53]. In contrast to our data, Lommatzsch et al. (2005) reported a decrease in BDNF levels
with increasing age or body weight, and there was a negative correlation of plasma BDNF values
with BMI [54]. However, similar to our findings of nominally lower plasma BDNF levels in female
versus male healthy subjects, women displayed lower platelet BDNF concentrations in comparison
to men in the aforementioned study; although, when matched for weight, there were no significant
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gender differences regarding BDNF plasma levels [54]. Therefore, it is plausible that the nominally
lower plasma BDNF levels seen in our female healthy subjects, showing no significant differences
after correction for multiple testing, could be due to the lower weight of women than men in the
control group. Regarding the association between smoking and BDNF levels, there are discrepancies
in the literature, demonstrating lower [55], higher [56], or unchanged [57] concentrations of BDNF
in the serum or plasma of smokers compared to nonsmokers. Though these reports on circulating
concentrations of BDNF are inconclusive, it is important to recognize that cigarette smoke, at least
partly through oxidative stress, has been shown to increase the expression of BDNF and its receptors
in airway smooth muscle cells [58]. This smoke-induced enhancement of neurotrophin release and
signaling may also occur in other cell types (e.g., epithelium and immune cells), thus contributing
to variations in both circulating and local concentrations [58]. Given that BDNF itself mediates both
short-term and long-term effects on airway smooth muscle cells after cigarette smoke exposure [58],
we surmise that the BDNF levels of the former smokers in the non-smoking cohorts of our study may
have off-set any potential differences in the BDNF concentrations of the never-smokers in both the
asthma and control groups.
Our finding that asthma patients had significantly higher concentrations of plasma BDNF than
healthy individuals is in contrast to earlier studies that reported no differences in the serum and sputum
BDNF levels between healthy subjects and patients with asthma [23,24]. Nevertheless, our data are in
line with the report on increased BDNF levels in the serum, platelets, and plasma of asthma patients
compared to the control group [21,59]. It has also been shown that children with moderate and severe
asthma had higher plasma BDNF levels than age-matched control subjects [22]. Moreover, the study of
Freeman et al. (2017) demonstrated higher BDNF expression and secretion in airway smooth muscle of
asthma patients compared to patients without asthma [60].
A recent study, showing higher amounts of mature BDNF in the sputum of patients with
severe asthma in comparison to healthy subjects, has suggested a possible association of BDNF
expression with asthma severity [61]. However, our investigation found that while both the non-severe
and severe asthma patients had significantly higher plasma BDNF concentrations than the control
subjects, there was no difference in the plasma BDNF levels between these groups of asthma patients.
Therefore, our findings imply that BDNF could serve as a potential biomarker of asthma, but not
asthma severity. This is in contrast to the previously reported data suggesting BDNF as a potential
biomarker for clinical severity of asthma in children [22]. These discrepancies might be explained by
the fact that Muller et al. (2010) compared the plasma BDNF of pediatric patients categorized into
three groups based on asthma severity (mild, moderate, and severe) [22], whereas our study examined
the plasma BDNF levels of non-severe (mild and moderate) versus severe asthma in adult patients.
On the other hand, the findings of our study are in line with the data of Szczepankiewicz et al. (2012),
demonstrating similar serum BDNF levels in children with asthma of different severity, regardless of
symptom activity [62]. Although differences in plasma BDNF concentration between non-severe and
severe asthma patients were not observed in our study, there was a nominally positive correlation
between plasma BDNF concentration and duration of asthma. The latter is usually also related to the
severity of the disease. However, some studies reported no correlation of serum BDNF levels with
asthma duration [63].
In our study, asthma patients with a history of pneumonia had nominally lower plasma BDNF
concentrations in comparison to asthma patients who had never developed pneumonia. Lommatsch
and co-authors (2007), however, reported markedly reduced BDNF concentrations in the serum
and platelets, but not plasma, of patients with acute bacterial lower respiratory tract infection,
with normalization to control BDNF levels after antibiotic treatment [64]. Previous studies regarding
the effect of viral infections on peripheral BDNF levels were contradictory, with the most recent
research by Azoulay et al. (2020) revealing lower serum BDNF levels in patients with severe or
moderate SARS-CoV-2 infection, followed by restoration of BDNF levels as patients recovered [65].
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Further research is required to clarify the acute and long-term effects of respiratory tract infections on
peripheral BDNF levels in the general population, and specifically, in asthma patients.
Interestingly, we observed the opposite trend of increased plasma BDNF levels in asthma
patients with nasal polyps, as well as in those with aspirin sensitivity. As pertains to nasal polyps,
Coffey et al. (2009) contrarily reported a decreased mean BDNF concentration, albeit in the sinus
mucosa of patients with chronic rhinosinusitis compared to controls, and patients with nasal polyps
had the most significant decrease [66]. On the other hand, our results are consistent with the findings
of Jornot and colleagues (2007) in nasal polyps, showing that polyp epithelial cells expressed higher
BDNF levels compared to turbinate-derived cells, and that BDNF secretion and production were
markedly increased in response to pro-inflammatory cytokines [67]. As far as we are aware, there are
currently no published data on BDNF levels in relation to aspirin sensitivity. More research is needed
to define the role of BDNF in nasal polyps and aspirin sensitivity in asthma.
When patients were subdivided into those with or without AERD according to the presence or
absence of the triad of clinical features (asthma, recurrent nasal polyps, and sensitivity to aspirin or
other NSAIDs), nominally higher BDNF levels were observed in patients with AERD. To the best of
our knowledge, there are no published data on BDNF levels in AERD patients. The importance of
this asthma phenotype is underscored by the increased associated morbidity and costs, as well as its
prevalence of 7.15% in asthma patients, as confirmed in our study (7.5%), and 14.89% in patients with
severe asthma [68].
Plasma BDNF concentrations in our study did not differ significantly between the non-allergic
and allergic asthma patients. This finding is in keeping with the study demonstrating no differences in
the serum BDNF levels between patients with allergic asthma and healthy individuals [23], or between
children with allergic asthma and those without an atopic background [62], as well as with the report
of no association between atopy and BDNF concentrations in the serum of patients with chronic
cough [24]. However, our results did not mirror earlier studies showing that patients with allergic
asthma have higher BDNF levels compared to control subjects [21,59]. Virchow et al. (1998) reported
that BDNF is produced endobronchially following allergen provocation, suggesting a contribution to
the pathogenesis of asthma [69]. In contrast to the study demonstrating lower amounts of BDNF in
the eosinophil lysates of allergic asthma patients than control subjects [70], or the report on higher
total BDNF in subjects with sputum eosinophilia [61], our study observed no differences in the plasma
BDNF concentration between patients with and without eosinophilic asthma. As far as we are aware,
our work is the first to compare the plasma BDNF levels between T2-low and T2-high asthma patients;
therefore, our results showing no differences could not be evaluated against the literature data.
The BDNF Val66Met polymorphism has previously been associated with asthma in children of
Chinese Han [7,30] and Slovak origin [15]; whereas a recent meta-analysis has suggested that the G
allele of BDNF Val66Met polymorphism is potentially associated with asthma risk in Caucasians [71].
However, in our study, no significant differences in the frequencies of BDNF Val66Met genotypes,
alleles or carriers were found between the asthma patients and control group. Our findings are
consistent with reports of no association of BDNF Val66Met polymorphism with the presence of
asthma in children [28], as well as with asthma-related phenotypes in families with asthma [29],
suggesting that this BDNF gene variation does not contribute significantly to asthma susceptibility or
severity. However, the same group of authors later reported that BDNF Val66Met polymorphism in a
haplotype (TTGC) with three other BDNF polymorphisms may contribute to asthma susceptibility,
but does not influence asthma severity [72]. These findings are in agreement with our study, which found
no significant differences in the frequencies of BDNF Val66Met genotypes, alleles, and carriers between
non-severe and severe asthma patients. In contrast, the study of Zeilinger et al. (2009) suggested that
BDNF Val66Met polymorphism contributes to the severe forms of asthma [31].
Regarding BDNF Val66Met polymorphism, it has been shown that the Met variant alters the
intracellular trafficking and packaging of pro-BDNF, resulting in reduced secretion of the mature
BDNF [25,73]. However, various studies reported contradictory findings about the possible influence
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of functional BDNF Val66Met polymorphism on BDNF levels, demonstrating that carriers of the
Met allele have decreased [74], increased [75], or unchanged [76] serum BDNF levels. In our study,
healthy individuals carrying the Met allele had significantly lower plasma BDNF levels in comparison
to the carriers of the Val/Val genotype, supporting the findings that BDNF Val66Met polymorphism
influences BDNF concentration in plasma. On the other hand, this association was not found in asthma
patients, as no significant differences in plasma BDNF levels were observed when the patients were
subdivided according to BDNF Val66Met genotypes and carriers. Our results in asthma patients
are in agreement with the data showing that BDNF Val66Met variants do not affect the BDNF
serum levels in children with asthma [32]. It is possible that in patients with asthma, due to the
complex pathophysiology of this disease, other factors predominantly influence BDNF plasma levels,
masking the effect of the functional BDNF Val66Met polymorphism.
In the present study, there were no differences in the distribution of BDNF Val66Met genotypes,
alleles or carriers between the non-allergic and allergic asthma patients. This is in line with the reported
lack of difference in the genotype distribution for clinical atopy between asthmatic patients and healthy
subjects [28], and with no association of BDNF Val66Met polymorphism with asthma-related atopy [29]
or asthma and any atopic disease in the cross-sectional study population [31]. In contrast, some reports
have suggested an important contribution of BDNF variations in the predisposition and progression of
allergic diseases [77,78]. To the best of our knowledge, the distribution of BDNF Val66Met variants
among different asthma phenotypes (T2-low vs. T2-high, eosinophilic vs. non-eosinophilic, and AERD
vs. non-AERD) has not been investigated so far; therefore, our results showing no differences could
not be discussed here in relation to the available literature.
Our study observed no differences in the distribution of NTRK2 rs1439050 genotypes, alleles,
and carriers between healthy subjects and asthma patients, and between patients of different
asthma severity or phenotypes. To the best of our knowledge, the association of NTRK2 rs1439050
polymorphism with asthma, its severity and particular phenotypes has not been explored so far.
However, some studies have examined other polymorphic variants within genes encoding neurotrophic
receptors, including TrkB gene in asthma [20,32]. Some of the studied polymorphisms represent
functional variants that may affect TrkB receptor expression. Higher TrkB expression has been found
in asthma patients compared to healthy controls [20,60], and in bronchial eosinophils after segmental
allergen provocation [79], but no differences in TrkB expression were observed between healthy subjects
and patients with allergies in peripheral blood mononuclear cells [80]. Markedly increased mRNA
levels of TrkB have also been detected in the inflamed lung tissue of a murine model of asthma [81].
In addition, cigarette smoke has been shown to be a potent inducer of TrkB expression and signaling in
airway smooth muscle [58], thus contributing to airway hyperresponsiveness in allergic asthma [82].
In addition to the TrkB receptor levels, polymorphic variants of neurotrophic receptor genes might
also affect the concentrations of unbound/active BDNF protein. However, similar to the findings of
Szczepankiewicz et al. [32], in our study plasma BDNF levels were not influenced by NTRK2 rs1439050
polymorphism in both healthy individuals and asthma patients.
It is important to acknowledge several limitations of the present study. First, control subjects
and asthma patients were not matched in their demographic parameters, such as age, gender,
and smoking status. Another limitation of this study is that we did not gather any data about the
physical activity and/or exercise regimen of the enrolled subjects. Specifically, increased peripheral
lactate levels following high intensity exercise have been associated with increased peripheral BDNF
concentrations [83]. Therefore, future studies should take into account the physical activity of
participants and its potential influence on plasma BDNF levels. Moreover, the exclusion criteria of
this study were quite restrictive and future studies should be conducted on much larger samples
of asthma patients, taking into account the effects of comorbidities and medications, to reflect the
real-world data. As the role of depression in asthma is an ongoing area of research [84–86], it would
be important to also incorporate these patients in future studies. On the other hand, the present
study included an adequate number of participants in order to have statistical power and to observe
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statistically significant associations. Another strength of the current study is that it enrolled an
ethnically homogenous population, consisting of Caucasian Croatians, which is especially important
for genetic studies. Additionally, this study took into consideration asthma severity and several asthma
phenotypes (T2-high and T2-low, non-allergic and allergic, non-eosinophilic, and eosinophilic, as well
as non-AERD and AERD), which have not been covered adequately in previous studies and should be
studied more extensively in the future.
5. Conclusions
In conclusion, our findings indicate that asthma patients have higher plasma BDNF levels than
healthy subjects. This may be due to a compensatory mechanism involving the activation of immune
cells in asthma. According to our results, plasma BDNF levels cannot be used to distinguish severe from
non-severe disease or between the different asthma phenotypes (allergic versus non-allergic, T2-high
versus T2-low, or non-eosinophilic versus eosinophilic asthma). On the other hand, significantly and
nominally higher plasma BDNF levels were observed in patients with aspirin-sensitive asthma and
AERD, respectively.
The genotype and allele frequencies of BDNF Val66Met and NTRK2 rs1439050 polymorphisms did
not differ between healthy individuals and asthma patients, nor between patients grouped according
to severity or different asthma phenotypes. Plasma BDNF concentration was not influenced by NTRK2
rs1439050 polymorphism in both healthy subjects and asthma patients. In contrast to the control group,
plasma BDNF concentrations in the asthma patients were not affected by the BDNF Val66Met genotype,
allele, or carrier distribution. Therefore, plasma BDNF levels in asthma patients are likely influenced
by a complex interaction between environmental factors and genetic predisposition, and might be
primarily related to the pathophysiology of the disease. Overall, our results suggest that BDNF
may be a useful peripheral blood biomarker of asthma in general, and especially for asthma with
aspirin sensitivity. However, additional studies, including larger numbers of subjects, are needed
in order to assess the clinical impact of these findings. Moreover, further research is warranted
to better understand the role of peripheral BDNF levels, as well as BDNF and NTRK2 (TrkB gene)
polymorphisms, in adult asthma.
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50. Glavak Tkalić, R.; Miletić, G.-M.; Sakoman, S. Prevalence of substance use among the general population:
Situation in Croatia and comparison with other European countries. Druš. Istraž. 2013, 22, 557–578.
[CrossRef]
51. Katsaounou, P.; Ioannou, M.; Hyland, M.E.; Odemyr, M.; Spranger, O.; Lindberg, A.; Gasser, M.; Conde, L.G.;
Jaumont, X.; Kasujee, I. Smoking asthmatics, a neglected large phenotype of asthmatic patients. Open J. Asthma
2019, 3, 1–8. [CrossRef]
52. Sustar, A.; Perkovic, M.N.; Erjavec, G.N.; Strac, D.S.; Pivac, N. Association between reduced brain-derived
neurotrophic factor concentration & coronary heart disease. Indian J. Med. Res. 2019, 150, 43–49. [CrossRef]
53. Pillai, A.; Bruno, D.; Sarreal, A.S.; Hernando, R.T.; Saint-Louis, L.A.; Nierenberg, J.; Ginsberg, S.D.; Pomara, N.;
Mehta, P.D.; Zetterberg, H.; et al. Plasma BDNF levels vary in relation to body weight in females. PLoS ONE
2012, 7, e39358. [CrossRef]
54. Lommatzsch, M.; Zingler, D.; Schuhbaeck, K.; Schloetcke, K.; Zingler, C.; Schuff-Werner, P.; Virchow, J.C.
The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005,
26, 115–123. [CrossRef] [PubMed]
55. Bhang, S.Y.; Choi, S.W.; Ahn, J.H. Changes in plasma brain-derived neurotrophic factor levels in smokers
after smoking cessation. Neurosci. Lett. 2010, 468, 7–11. [CrossRef] [PubMed]
56. Jamal, M.; Van der Does, W.; Elzinga, B.M.; Molendijk, M.L.; Penninx, B.W. Association between
smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum.
Nicotine Tob. Res. 2015, 17, 323–329. [CrossRef] [PubMed]
57. Xia, H.; Du, X.; Yin, G.; Zhang, Y.; Li, X.; Cai, J.; Huang, X.; Ning, Y.; Soares, J.C.; Wu, F.; et al. Effects of
smoking on cognition and BDNF levels in a male Chinese population: Relationship with BDNF Val66Met
polymorphism. Sci. Rep. 2019, 9, 217. [CrossRef]
58. Sathish, V.; Vanoosten, S.K.; Miller, B.S.; Aravamudan, B.; Thompson, M.A.; Pabelick, C.M.; Vassallo, R.;
Prakash, Y.S. Brain-derived neurotrophic factor in cigarette smoke-induced airway hyperreactivity. Am. J.
Respir. Cell. Mol. Biol. 2013, 48, 431–438. [CrossRef]
59. Noga, O.; Hanf, G.; Schäper, C.; O’Connor, A.; Kunkel, G. The influence of inhalative corticosteroids
on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic
asthmatics. Clin. Exp. Allergy 2001, 31, 1906–1912. [CrossRef]
60. Freeman, M.R.; Sathish, V.; Manlove, L.; Wang, S.; Britt, R.D., Jr.; Thompson, M.A.; Pabelick, C.M.; Prakash, Y.S.
Brain-derived neurotrophic factor and airway fibrosis in asthma. Am. J. Physiol. Lung Cell. Mol. Physiol.
2017, 313, L360–L370. [CrossRef]
61. Watanabe, T.; Fajt, M.L.; Trudeau, J.B.; Voraphani, N.; Hu, H.; Zhou, X.; Holguin, F.; Wenzel, S.E. Brain-derived
neurotrophic factor expression in asthma. Association with severity and type 2 inflammatory processes.
Am. J. Respir. Cell. Mol. Biol. 2015, 53, 844–852. [CrossRef]
62. Szczepankiewicz, A.; Rachel, M.; Sobkowiak, P.; Kycler, Z.; Wojsyk-Banaszak, I.; Schöneich, N.; Skibinska, M.;
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